


Express Mail No.: EV 922211434 US
Date of Deposit: March 18, 2008



Page 1 of 3
Attorney Docket No.: 34251-501 NATL

Modified Form 1449/PTO		Application Number	10/576,861
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 2, 2007
		First Named Inventor	Verheijen
		Group Art Unit	1625
		Examiner Name	Taofiq A. Solola
		Attorney Docket Number	34251-501 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
*A1	4,791,107	12/13/88	Hamer et al.	514	228.2		
*A2	4,948,807	08/14/90	Rosin et al.	514	484		
*A3	5,187,165	02/16/93	Hamer et al.	514	307		
*A4	5,302,721	04/21/94	Wong et al.	548	429		
*A5	5,409,948	04/25/95	Greig et al.	514	411		
*A6	5,455,354	10/03/95	Wong et al.	546	147		
*A7	5,602,176	02/11/97	Enz	514	490		
*A8	5,665,880	09/09/97	Lee et al.	546	147		
*A9	5,677,457	10/14/97	Lee et al.	546	141		

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
*A10		2005/0096387 A1	05/05/05	Verheijen et al.	514	478	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B1	DE	38 05 744 A1	SANDOZ-PATENT-GMBH	09/15/88	
B2	FR	2 719 047 A1	FABRE MEDICAMENT PIERRE	10/27/95	
B3	WO	96/02524 A1	MEDIOLANUM FARMACEUTICI S.P.A.	02/01/96	
B4	WO	97/14694	ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE	04/24/97	
B5	WO	97/23484	ASTRA AKTIBOLAG	07/03/97	

OTHER PRIOR ART—NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Amstutz et al., "Cyclische Phenyl-carbamate des Miotin-Typs und ihre Wirkung auf die Acetylcholinesterase", <i>Helvetica Chimica Acta</i> , 73:739-753 (1990) (English Abstract Only)
	C2	Brossi et al., "Invited Review. Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties", <i>Aust. J. Chem.</i> , 49:171-181 (1996)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C3	Cutler et al., "Muscarinic M ₁ -Receptor Agonists: Potential in the Treatment of Alzheimer's Disease", <i>CNS Drugs</i> , 3(6):467-481 (1995)
	C4	Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Koyama et al., "Pharmaceuticals containing (hydroxybenzyl) amines as acetylcholine esterase inhibitors and selective serotonin reuptake inhibitors", XP002331878 retrieved from STN Database accession No. 2004:291183 abstract & JP 2004 107322 A2 (BTG INTERNATIONAL LTD., UK) 8 April 2004 (2004-04-08)
	C5	Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Goto et al., "Preparation of aromatic carbamates as choline esterase inhibitors for improvement of cerebral function", XP002331879 retrieved from STN Database accession No. 1991:206818 abstract & JP 03 002155 A2 (TAKEDA CHEMICAL INDUSTRIES, LTD., JAPAN) 8 January 1991 (1991-01-08)
	C6	Database Beilstein, Beilstein Institut Fuer Chemische Wissenschaften, Frankfurt Am Main, DE, XP002331880
	C7	De Sarno et al., "The Effect of Heptyl-Physostigmine, a New Cholinesterase Inhibitor, on the Central Cholinergic System of the Rat", <i>Neurochem. Res.</i> , 14(10):971-977 (1989)
	C8	Elmalem et al., "Antagonism of Morphine-Induced Respiratory Depression by Novel Anticholinesterase Agents", <i>Neuropharmacol.</i> , 30(10):1059-1064 (1991)
	C9	Froestl et al., "SGS742: the first GABA _B receptor antagonist in clinical trials", <i>Biochem. Pharmacol.</i> , 68:1479-1487 (2004)
	C10	Gatto et al., "TC-1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long-Lasting Cognitive Effects", <i>CNS Drug Reviews</i> , 10(2):147-166 (2004)
	C11	Heinonen et al., "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans", <i>J. Clin. Pharmacol.</i> , 37:602-609 (1997)
	C12	Janssen et al., "Does phenylethylamine act as an endogenous amphetamine in some patients?", <i>Int. J. Neuropsychopharmacol.</i> , 2:229-240 (1999)
	C13	Kerr et al., "GABA _B Receptors", <i>Pharmac. Ther.</i> , 67(2):187-246 (1995)
	C14	Korczyn, A.D., "Muscarinic M ₁ agonist in the treatment of Alzheimer's disease", <i>Exp. Opin. Invest. Drugs</i> , 9(10):2259-2267 (2000)
	C15	Kupsch, A., "Rasagiline Teva Pharmaceutical", <i>Curr. Opin. Investig. Drugs</i> , 3(5):794-979 (2002)
	C16	Land et al., "D-Cycloserine: Effects on Long-Term Retention of a Conditioned Response and on Memory for Contextual Attributes", <i>Neurobiol. Learning Mem.</i> , 72(3):158-168 (1999)
	C17	Lipiello et al., "RJR-2403 is an Efficacious Agonist for Human α4β2 Neuronal Nicotinic Acetylcholine Receptors with Lower Efficacy for Other Human Receptor Subtypes", <i>Soc. Neurosci.</i> , 24:88 (Abstract 39.26) (1998)
	C18	Obinu et al., "Brain Selective Stimulation of Nicotinic Receptors by RJR 1734 Enhances ACh Transmission From Frontoparietal Cortex and Enhances Memory in Rodents", <i>Internat. J. Neuropsychopharmacology</i> , 3(Suppl. 1):S361 (2003) (Abstract Only)
	C19	Obinu et al., Brain Selective Stimulation of Nicotinic Receptors by TC-1734 Enhances Ach Transmission From Frontoparietal Cortex and Enhances Memory in Rodents", <i>Progress in Neuropsychopharmacol. & Biol. Psychiatry</i> , 26:913-918 (2002)

Express Mail No.: EV 922211434 US
Date of Deposit: March 18, 2008

Page 3 of 3
Attorney Docket No.: 34251-501 NATL

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20	Parsons et al., "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data", <i>Neuropharmacol.</i> , 38(5):735-767 (1999)
	C21	Rampa et al., "Acetylcholinesterase Inhibitors: SAR and Kinetic Studies on ω -[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl Derivatives", <i>J. Med. Chem.</i> , 44:3810-3820 (2001)
	C22	Sterling et al., "Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease", <i>J. Med. Chem.</i> , 45:5260-5279 (2002)
	C23	Trabace et al., "CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor", <i>CNS Drug Reviews</i> , 8(1):53-69 (1992)
	C24	Tumiatti et al., "[4-[[N-(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit on the Potency for Muscarinic Receptors", <i>Bioorg. Med. Chem.</i> , 8:681-689 (2000)
	C25	Yang et al., " β -Phenylethylamine: A Specific Substrate for Type B Monoamine Oxidase of Brain", <i>J. Pharmacol. Exp. Ther.</i> , 187(2):365-371 (1973)

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A9 and U.S. Published Application A10 are not submitted.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4264920v.1